IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR Russian patent published in 2019 - IPC G01N33/74 

FIELD: pharmaceuticals.

SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a method of determining the need of a cancer patient in a combined therapy using a PD-L1 inhibitor – programmed cell death ligand-1, wherein a therapy comprising a modulator of the HER2/neu (ErbB2) signalling pathway and a chemotherapeutic agent, or in which the patient is exposed to a therapy comprising a HER2/neu (ErbB2) signal path modulator and a chemotherapeutic agent; including steps of: measuring in vitro in a sample from the body of said patient levels of expression of the receptor estrogen (ER), PD-L1 and gamma-interferon (IFNγ) and classifying said patient as in need of a combined therapy using a PD-L1 inhibitor, if ER-negative level of expression is established, increased level of expression of PD-L1 in comparison with threshold value PD-L1 and reduced level of IFNγ expression in comparison with IFNγ threshold value. Inventions also include use of Her2/neu (ErbB2) signalling pathway, PD-L1 inhibitor and chemotherapeutic agent, as well as a pharmaceutical composition containing said agents, in treating cancer, wherein for this cancer an ER-negative expression level, an increased level of PD-L1 expression as compared to a PD-L1 threshold value and a reduced level of IFNγ expression in comparison with IFNγ threshold value.

EFFECT: group of inventions enables to determine whether a patient requires a combined therapy using a PD-L1 inhibitor and a modulator of the HER2/neu (ErbB2) signalling pathway for treating cancer.

25 cl, 19 dwg, 6 tbl, 1 ex